Clinical Trial Update: Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome [Phase 1]

View source ↗

Summary

Phase 1 study of SGR-2921 in relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• SGR-2921

Snippet

Sponsor: Schrödinger, Inc. | Conditions: Acute Myeloid Leukemia, High-Risk and Very High-Risk Myelodysplastic Syndromes | Phase 1 | Status: TERMINATED